Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 12/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.73 |
| ▸ | CCND1 | P24385 | 5/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.60 |
| ▸ | CDK2 | P24941 | 5/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.60 |
| ▸ | CDK4 | P11802 | 3/20 | 0.59 |
| ▸ | CCND3 | P30281 | 3/20 | 0.59 |
| ▸ | CCND2 | P30279 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305016 | 1.00 | MAPK8 (0.73) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL16802606 | 0.88 | MAPK8 (0.73) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL18148245 | 0.88 | MAPK8 (0.73) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL24670367 | 0.87 | CCND1 (0.72) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL3304431 | 0.87 | CCND1 (0.72) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL16799550 | 0.85 | MAPK8 (0.73) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL18163284 | 0.85 | MAPK8 (0.79) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL16802596 | 0.85 | MAPK8 (0.82) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL18148266 | 0.84 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CCND1CCNE1 | |
| SCHEMBL16802728 | 0.84 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2010046273-A2 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | MAP3K20, MAP3K6, MAP3K1 | MAPK8 36/4885MAPK10 38/4885MAPK9 37/4885 |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK10 31/4885MAPK9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.